Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aspen Pharmacare Holdings Ltd updates on acquisition by of Glaxosmithkline Group’s Arixtra And Fraxipa


Tuesday, 31 Dec 2013 04:00am EST 

Aspen Pharmacare Holdings Ltd:Refers to earlier announcements, wherein it was confirmed that the Aspen Group had entered into an agreement with GSK in terms whereof Aspen would acquire.The Business - the business carried on by GSK in respect of the commercialisation of Arixtra, Fraxiparine and Fraxodi trademarks, as marketed by GSK or its distributors in the world, India and Pakistan – with effect from Jan. 1, 2014 and.The Manufacturing Business - business carried out at the Notre Dame de Bondeville manufacturing site relating to the manufacture of the Products for commercialisation in the Relevant Markets and Excluded Territories and the manufacture of diluents for GSK, during Q2 2014.Says all conditions precedent have been met in respect of the acquisition of the Business and the Manufacturing Business.Says as a result the acquisition of the Business has completed with effect from tDec. 31 and all of the material commercial operations related to the Business will therefore transfer to Aspen on Jan. 1, 2014.Says the acquisition of the Manufacturing Business is expected to complete during the second quarter of 2014. 

Company Quote

30199.0
-201.0 -0.66%
22 Aug 2014